Alkermes ALKS
NASDAQ ALKS
$45.43 -0.06 (-0.13%)
As of: Sep 9, 2026 · 1:23 PM EDT

Alkermes (ALKS) Income from Continuing Operations (2010 - 2026)

Alkermes' (ALKS) quarterly Income from Continuing Operations came in at $524000.0 in Q2 2026, down 99.4% year-over-year from $87.1 million in Q2 2025, and up 100.79% quarter-over-quarter from -$66.5 million in Q1 2026.

Analysis

Alkermes (ALKS) Income from Continuing Operations (2010 - 2026) Analysis & Trends

Alkermes (ALKS) has reported Income from Continuing Operations for 17 consecutive years, with $524000.0 the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Income from Continuing Operations fell 99.4% year-over-year to $524000.0 in Q2 2026; TTM through Jun 2026 was $66.1 million, a 81.0% decrease from a year earlier, with the FY2025 full-year figure at $241.7 million, down 35.06% from the prior year.
  • Income from Continuing Operations was $524000.0 for Q2 2026 at Alkermes, up from -$66.5 million in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at $279.1 million in Q2 2023 and troughed at -$66.5 million in Q1 2026.
  • A 5-year average of $56.9 million and a median of $66.1 million in 2025 frame the typical range for Income from Continuing Operations.
  • Across the five-year window, Income from Continuing Operations slumped 1374.79% in 2022 and soared 1026.14% in 2023, its largest moves.
  • Over 5 years, Income from Continuing Operations stood at $87.7 million in 2022, then jumped by 83.04% to $160.6 million in 2023, then declined by 9.2% to $145.8 million in 2024, then plunged by 66.12% to $49.4 million in 2025, then tumbled by 98.94% to $524000.0 in 2026.
  • The last three Income from Continuing Operations figures came in at $524000.0 (Q2 2026), -$66.5 million (Q1 2026), and $49.4 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Johnson & Johnson 644.32 Bn 623.56 Bn 17.26 Bn 5.53 Bn
2 AbbVie 440.60 Bn 434.04 Bn 12.70 Bn 3.62 Bn
3 Merck 365.39 Bn 358.25 Bn 12.21 Bn -1.34 Bn
4 Novartis Ag 266.73 Bn 259.04 Bn 11.24 Bn 5.28 Bn
5 Pfizer 159.22 Bn 147.52 Bn 10.94 Bn -246.00 Mn
6 Sanofi 52.48 Bn 45.10 Bn 10.79 Bn 2.16 Bn
7 Revolution Medicines 44.21 Bn 44.21 Bn - -644.37 Mn
8 Incyte 25.34 Bn 20.81 Bn 1.57 Bn 585.61 Mn
9 United Therapeutics 21.49 Bn 18.82 Bn 683.80 Mn 333.00 Mn
10 Alkermes 7.58 Bn 6.93 Bn 397.90 Mn 524,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 524,000.00
Mar 31, 2026 -66.53 Mn
Dec 31, 2025 49.39 Mn
Sep 30, 2025 82.75 Mn
Jun 30, 2025 87.10 Mn
Mar 31, 2025 22.46 Mn
Dec 31, 2024 145.78 Mn
Sep 30, 2024 92.80 Mn
Jun 30, 2024 94.62 Mn
Mar 31, 2024 38.91 Mn
Dec 31, 2023 160.55 Mn
Sep 30, 2023 91.51 Mn
Jun 30, 2023 279.10 Mn
Mar 31, 2023 -12.05 Mn
Dec 31, 2022 87.72 Mn
Sep 30, 2022 -63.97 Mn
Jun 30, 2022 -30.14 Mn
Mar 31, 2022 -35.90 Mn
Dec 31, 2021 125.44 Mn
Sep 30, 2021 -28.99 Mn